Iasibon (ibandronic acid)
- Region
- 🇪🇺 EU
- Active substance
- ibandronic acid
- Company
- Pharmathen S.A.
- Status
- Authorised
- Therapeutic area
- Hypercalcemia; Fractures, Bone; Neoplasm Metastasis; Breast Neoplasms
- CHMP opinion
- Thu 21 Oct 2010
- EU approval
- Fri 21 Jan 2011
- Designations
- Generic
- Application
- EMEA/H/C/002025
- ATC
- M05BA06
- Official record
- www.ema.europa.eu
Indication
Concentrate for solution for infusion Prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases. Treatment of tumour-induced hypercalcaemia with or without metastases. Film-coated Tablets Prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Ibandronic Acid Sandoz Lapsed · Sandoz GmbH
- 🇪🇺 Ibandronic acid Accord Authorised · Accord Healthcare S.L.U.
- 🇪🇺 Bonviva Authorised · Atnahs Pharma Netherlands B.V.
- 🇪🇺 Bondronat Authorised · Atnahs Pharma Netherlands B.V.
- 🇪🇺 Ibandronic Acid Teva Authorised · Teva Pharma B.V.
- 🇪🇺 Bondenza (previously Ibandronic Acid Roche) Withdrawn · Roche Registration Ltd.
- 🇪🇺 Ibandronic Acid Hexal Application withdrawn · Hexal AG
- 🇪🇺 Destara Withdrawn · Roche Registration Ltd.
Follow Iasibon
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.